迪安诊断 (300244.SZ) Stock Price, Financials & Summary | drillr

Skip to content

Sign in Sign up

Price chart

Aug 6Aug 11Aug 14Aug 19Aug 24Aug 27Sep 1Sep 4

ValuationView details →

P/E (Fwd)

23.7x

EV/EBITDA

18.9x

Market Cap

CNY 12.39B

MomentumView details →

1D Return

−4.02%

YTD Return

+12.18%

RSI (14)

39.6

ValuationView details →

P/E (Fwd)

23.7x

EV/EBITDA

18.9x

Market Cap

CNY 12.39B

RSI (14)

39.6

MomentumView details →

1D Return

−4.02%

YTD Return

+12.18%

ProfitabilityView details →

Gross Margin

29.18%

Net Margin

1.30%

EBITDA Margin

7.00%

ROE (TTM)

1.98%

ROA (TTM)

0.92%

Asset Turnover

0.70x

GrowthView details →

Revenue YoY

−13.90%

EPS YoY

+132.48%

FCF YoY

+91.07%

Revenue CAGR 3Y

−20.75%

EPS CAGR 3Y

−68.48%

EBITDA YoY

—

EarningsView details →

EPS (Actual)

CNY 0.27

EPS Surprise

12.49%

Beats (12Q)

1/12

Next Q EPS Est

CNY 0.20

Avg Surprise (4Q)

12.49%

Rev Surprise

−4.88%

Capital & dividendView details →

Debt/Equity

0.24x

Current Ratio

2.73x

Quick Ratio

2.36x

Div Yield

1.97%

Div Rate

CNY 0.35

Div Growth 1Y

+40.00%

Financials snapshotView financials →

Revenue (TTM)

9.98B

Net Income (TTM)

129.43M

Op. CF (TTM)

2.03B

Next earningsOct 22, 2026 →

Latest newsMore news →

Di'an Diagnostics launched a new dual-sample tuberculosis molecular detection technology, the Jindi'an Mycobacterium tuberculosis complex nucleic acid detection kit (PCR-fluorescence probe method), developed with Shanghai Infection and Immunity Science and Technology Innovation Center, at the 37th National Academic Conference of the Chinese Anti-Tuberculosis Association on August 30, 2026.4d ago

Di'an Diagnostics announced its H1 2026 results: revenue of 4.773 billion yuan, down 3.30% year-on-year; net profit attributable to shareholders of 232 million yuan, up 2160.87% year-on-year; non-recurring net profit of 239 million yuan, up 2685.60% year-on-year.15d ago

Similar companies

华厦眼科301267.SZ 三博脑科301293.SZ 国际医学000516.SZ 美年健康002044.SZ 创新医疗002173.SZ 新里程002219.SZ Find similar companies →

Latest newsMore news →

Di'an Diagnostics launched a new dual-sample tuberculosis molecular detection technology, the Jindi'an Mycobacterium tuberculosis complex nucleic acid detection kit (PCR-fluorescence probe method), developed with Shanghai Infection and Immunity Science and Technology Innovation Center, at the 37th National Academic Conference of the Chinese Anti-Tuberculosis Association on August 30, 2026.4d ago Di'an Diagnostics announced its H1 2026 results: revenue of 4.773 billion yuan, down 3.30% year-on-year; net profit attributable to shareholders of 232 million yuan, up 2160.87% year-on-year; non-recurring net profit of 239 million yuan, up 2685.60% year-on-year.15d ago